A Genome-Wide Association Study in Psoriasis Patients Reveals Variants Associated with Response to Treatment with Interleukin-17A Pathway Inhibitors.

ABSTRACT:

Background/objectives

Psoriasis is currently treated with biologics targeting the IL-17A signaling, which plays a major role in immune response and keratinocyte hyperproliferation. These include inhibitors of IL-17A and/or its heterodimer with IL-17F (Secukinumab, Ixekinumab and Bimekizumab) and the receptor IL17-RA (Brodalumab). Although these drugs are safe and highly effective, there is significant variability in response among patients. This can be partly attributed to the patients' genetic background, thus pointing to the need to identify pharmacogenetic markers for treatment response.

Methods

The study involved 88 Greek patients who were treated with inhibitors of the IL-17A signaling for at least 6 months. Patients were classified as responders and non-responders acco

SUBMITTER: Ioakeimidou D 

PROVIDER: S-EPMC12564490 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature